Untangling the Vioxx-Celebrex Controversy: A Story about Responsibility

DSpace/Manakin Repository

Untangling the Vioxx-Celebrex Controversy: A Story about Responsibility

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Tran, Lan en_US
dc.date.accessioned 2012-06-15T20:25:49Z
dc.date.issued 2005 en_US
dc.identifier.citation Untangling the Vioxx-Celebrex Controversy: A Story about Responsibility (2005 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8889459
dc.description.abstract While the withdrawal of prescription drugs is not a new concept, the Vioxx and Celebrex controversy has put a new spin on the issue of withdrawal. Vioxx and Celebrex belong to the same class of drugs and both were linked to increased heart risks. While Merck chose to withdraw Vioxx from the market, Pfizer decided to keep Celebrex put, choosing instead to suspend all direct-to-consumer advertising and make small labeling changes. This paper attempts to construct a story about why these two companies took such contrasting reactions, which was right, and what should be done in the future. But before delving into that analysis, it is important to understand the background of the controversy, including the history and development of Vioxx and Celebrex, why they were approved in the first place, and the basis for such approvals. Next, it is crucial to comprehend the different medical studies that have been conducted, which are the basis on which action has been demanded from the companies. From there, it may then be possible to analyze the different actions taken by Merck and Pfizer and what resulted from such actions, which will allow for better basis in which to evaluate who was right. Finally, in every step of the controversy, the FDA’s actions will be examined, including its formal and informal guidance, regulatory powers, and an analysis of when and why it chooses to take or not take action. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject vioxx en
dc.subject celebrex en
dc.title Untangling the Vioxx-Celebrex Controversy: A Story about Responsibility en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-15T20:25:49Z

Files in this item

Files Size Format View
Tran05.pdf 2.088Kb PDF View/Open
Tran05.rtf 743.0Kb RTF file View/Open
Tran05.html 367.5Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters